辉瑞推飞三生国健

市场资讯
25 May

来源:富凯财经作者|辛思路富凯摘要一方在爆发,一方要突破。5月20日早间,三生制药宣布,公司及附属公司沈阳三生、三生国健已经与辉瑞签署独家许可协议,将向辉瑞独家授予公司自主研发的突破性PD-1/VEGF双特异性抗体SSGJ-707在全球(不包括中国内地)的开发、生产、商业化权利,同时保留中国内地的权益。据悉,三生制药此次出海交易获得的12.5亿美元首付款,刷新了国产创新药License-out(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10